A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in the Adjuvant Treatment of Patients With Stage III or High-risk Stage II Colorectal Cancer

This study is to evaluate PledOx for prevention of chronic chemotherapy induced peripheral neuropathy induced by oxaliplatin in patients with Stage III or high-risk Stage II colorectal cancer (CRC).

开始日期2019-01-07

申办/合作机构

Egetis Therapeutics AB

[+1]

NCT03654729

/ Terminated临床3期

This study evaluates the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by the drug oxaliplatin.

开始日期2018-11-07

申办/合作机构

Egetis Therapeutics AB

[+1]

NCT03430999

/ Completed临床1期

SUNCIST: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Intravenous Administration of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Randomized, double-bline, placebo-controlled, single dose study comparing the pharmacokinetics (PK) and safety of PP095-01 in Japanese and non-Asian (eg, Caucasian) subjects.

开始日期2017-11-07

申办/合作机构

Egetis Therapeutics AB

100 项与 Calmangafodipir 相关的临床结果

登录后查看更多信息

100 项与 Calmangafodipir 相关的转化医学

登录后查看更多信息

100 项与 Calmangafodipir 相关的专利（医药）

登录后查看更多信息

项与 Calmangafodipir 相关的文献（医药）

2025-12-01·Current Neurology and Neuroscience Reports

Recent Advances in Diagnosis, Management, Treatment, and Prevention of Neuropathies in Cancer Patients

Review

作者: Rhee, John Y ; Finnemore, Alexander ; Tentor, Zachary ; Cashman, Christopher ; Paulino, Maria T

PURPOSE OF REVIEW:

The purpose of this article is to provide an update on cancer-related neuropathies over the past five years, by reviewing the advances in pathophysiology and biology, diagnostic approaches, and management strategies.

RECENT FINDINGS:

New agents causing peripheral neuropathy include antibody-drug conjugates, combinations of immune-checkpoint inhibitor therapies, and targeted therapies. Development of axonal neuropathies has been found to be mediated through the protein sterile-α and Toll/interleukin 1 receptor motif containing protein 1 (SARM1). There have been emerging imaging modalities such as high-field MRI and neuromuscular ultrasound, and serum biomarkers, such as neurofilament light chain and glial fibrillary acid protein. Though calmangafodipir was negative for preventing peripheral neuropathy in oxaliplatin-based treatments, the POLAR trial randomizing patients to cooling or compression of the dominant hand during taxane administration significantly reduced incidence of chemotherapy-induced peripheral neuropathy. As of yet, there are no treatments for chemotherapy-induced peripheral neuropathy, but continued basic research into the SARM pathway is likely to yield novel agents that will stop, or prevent, the process.

2025-01-01·JOURNAL OF PHARMACOLOGICAL SCIENCES

Paclitaxel-induced peripheral neuropathy in male rats attenuated by calmangafodipir, a superoxide dismutase mimetic

Article

作者: Kawashiri, Takehiro ; Nagahama, Fumiko ; Kobayashi, Daisuke ; Mine, Keisuke ; Mori, Kohei ; Koura, Yusuke ; Ishida, Haruna ; Fujita, Shunsuke ; Yao, Kozo ; Ueda, Mami ; Mori, Yusuke ; Shimazoe, Takao

Paclitaxel induces peripheral neuropathy, which is considered a dose-limiting factor. However, appropriate prophylactic agents are currently unavailable. We investigated the prophylactic effects of calmangafodipir, a superoxide dismutase mimetic, on paclitaxel-induced peripheral neuropathy using a male rat model. Repeated administration of paclitaxel (6 mg/kg, intraperitoneal, once weekly for 4 weeks) resulted in mechanical allodynia in the von Frey test and axonal degeneration in the sciatic nerve. Conversely, calmangafodipir (1-10 mg/kg, intravenous, thrice weekly for 4 weeks) prevented mechanical allodynia and axonal degeneration induced by paclitaxel. These results suggest that calmangafodipir may inhibit paclitaxel-induced peripheral neuropathy.

2024-10-01·Biochemical pharmacology

Clinically relevant therapeutic approaches against acetaminophen hepatotoxicity and acute liver failure

Review

作者: Jaeschke, Hartmut ; Rumack, Barry H ; Akakpo, Jephte Y ; Curry, Steven C ; Ramachandran, Anup

Liver injury and acute liver failure caused by an acetaminophen (APAP) overdose is a significant clinical problem in western countries. With the introduction of the mouse model of APAP hepatotoxicity in the 1970 s, fundamental mechanisms of cell death were discovered. This included the recognition that part of the APAP dose is metabolized by cytochrome P450 generating a reactive metabolite that is detoxified by glutathione. After the partial depletion of glutathione, the reactive metabolite will covalently bind to sulfhydryl groups of proteins, which is the initiating event of the toxicity. This insight led to the introduction of N-acetyl-L-cysteine, a glutathione precursor, as antidote against APAP overdose in the clinic. Despite substantial progress in our understanding of the pathomechanisms over the last decades viable new antidotes only emerged recently. This review will discuss the background, mechanisms of action, and the clinical prospects of the existing FDA-approved antidote N-acetylcysteine, of several new drug candidates under clinical development [4-methylpyrazole (fomepizole), calmangafodipir] and examples of additional therapeutic targets (Nrf2 activators) and regeneration promoting agents (thrombopoietin mimetics, adenosine A2B receptor agonists, Wharton's Jelly mesenchymal stem cells). Although there are clear limitations of certain therapeutic approaches, there is reason to be optimistic. The substantial progress in the understanding of the pathophysiology of APAP hepatotoxicity led to the consideration of several drugs for development as clinical antidotes against APAP overdose in recent years. Based on the currently available information, it is likely that this will result in additional drugs that could be used as adjunct treatment for N-acetylcysteine.

项与 Calmangafodipir 相关的新闻（医药）

2026-03-09

·BioSpace

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's patent application No. 19/261,360 entitled "Pharmaceutical Compositions for Treating MCT8 Deficiency". Now that Egetis have paid the issue fee, this Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed. The allowed patent provides protection for a novel composition, which contains tiratricol as the active ingredient, designed to correct the disrupted thyroid hormone signaling characteristic of MCT8 deficiency. The allowed claims cover, among other things, a method of treating MCT8 deficiency with a pharmaceutical composition that encompasses tiratricol, including dosing regiments, and tiratricol compositions with specific excipients. This Notice of Allowance represents a significant milestone in strengthening the Company's intellectual property portfolio supporting its lead investigational therapy. Egetis expects the resulting patent will be Orange Book-listable, with an anticipated expiration date of 2045. Nicklas Westerholm, CEO, said: "We are very pleased to receive this Notice of Allowance, which reinforces the innovative nature of our therapeutic approach for patients with MCT8 deficiency. This accomplishment supports our commitment to advancing a much‑needed treatment option for this devastating disorder." Egetis also intends to seek corresponding patent protection in additional territories around the World, including Europe and Japan, based on a PCT International Patent Application that the Company has Egetis has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Emcitate ® (tiratricol) for the treatment of MCT8 deficiency on January 29, 2026. The FDA is expected to confirm within 60 days that the NDA submission is complete. As a designated Fast Track and Breakthrough Therapy, Egetis has requested Priority Review, and if granted, the FDA review should be completed within six months following the 60-day filing review period. Thus, Egetis anticipates regulatory decision on the NDA application in September 2026. For further information, please contact: Nicklas Westerholm, CEO +46 (0) 733 542 062 nicklas.westerholm@egetis.com Karl Hård, Head of Investor Relations & Business Development +46 (0) 733 011 944 karl.hard@egetis.com About Egetis Therapeutics Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment. The Company's lead drug candidate Emcitate ® (tiratricol) is developed for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In February 2025 the European Commission approved Emcitate ® as the first and only treatment for MCT8 deficiency in EU. Egetis initiated the launch of Emcitate ® in Germany on May 1, 2025. Emcitate ® (tiratricol) is not approved in the USA. The Company completed a rolling New Drug Application (NDA) for Emcitate ® (tiratricol) in the USA on January 29, 2026. The FDA is expected to confirm within 60 days that the NDA submission is complete. As a designated Fast Track and Breakthrough Therapy, Egetis has requested Priority Review, and if granted, the FDA review should be completed within six months following the 60-day filing review period. Based on feedback from the FDA, the NDA for Emcitate ® (tiratricol) for treatment of MCT8 deficiency will be based on currently available clinical data from Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study, EMC Survival Study and the US Expanded Access Program. Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation (RPDD) by the FDA, which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. The drug candidate Aladote ® (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for Aladote® has been parked. Aladote ® has been granted ODD in the US and in the EU. Egetis Therapeutics is listed on the Nasdaq Stockholm main market (Nasdaq Stockholm:EGTX). For more information, see Attachments Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S. SOURCE: Egetis Therapeutics View the original press release on ACCESS Newswire

孤儿药申请上市优先审批快速通道上市批准

2022-06-20

·凯莱英药闻

首个有机砷抗癌疗法DARVIAS在日本获批！用于治疗复发或难治性外周 T 细胞淋巴瘤

欢迎关注凯莱英药闻2022年6月19日，Solasia Pharma（简称“Solasia”）宣布，有机砷药物DARVIAS（darinaparsin）被日本厚生劳动省（MHLW）批准治疗复发或难治性外周 T 细胞淋巴瘤（以下简称“PTCL”）。本次获批是基于在亚洲多国针对复发或难治性 PTCL 患者进行的2期临床试验的积极结果，该药物此前已被美国和欧盟授予治疗PTCL的孤儿药资格。Darinaparsin药物介绍Darinaparsin（SP-02）是一种具有抗癌活性的有机砷化合物，是一种新型的线粒体靶向药物，被开发用于治疗多种血液系统癌症（淋巴瘤、白血病）和实体瘤。该药物的可能作用机制包括破坏线粒体的功能、增加的活性氧的产生，调节细胞内的信号转导通路等。Darinaparsin被认为能够通过诱导细胞周期停滞和细胞凋亡发挥抗癌作用。此前，Solasia从 Alaunos Therapeutics获得了darinaparsin的全球专利后进行开发，2021年10月，又宣布与Nippon Kayaku就darinaparsin的营销权达成许可协议。Darinaparsin的获批是基于一项在多国（包括日本、韩国、台湾和香港）、多中心、单臂、开放标签、非随机研究的积极结果，该研究评估了darinaparsin单药治疗复发或难治性PTCL患者的疗效、安全性和药代动力学数据，结论显示darinaparsin 具有临床疗效，在PTCL 患者中具有良好的耐受性，是治疗复发或难治性 PTCL 的潜在选择。根据2021 ASH上公布的数据，使用darinaparsin在治疗复发/难治性PTCL患者的2期临床试验中，客观缓解率（ORR）为19%；疾病控制率达到完全缓解（CR）、部分缓解（PR）或疾病稳定 (SD) 的患者比例为 46%，甚至更多超过一半的患者实现了肿瘤缩小；中位缓解持续时间 (DOR) 为 3.8 个月；中位无进展生存时间（PFS）和总生存率（OS）分别为3.3 个月和 13.7 个月。不良事件（AEs）发生率为97%，药物相关AEs发生率为68%。所有研究患者的药代动力学特征没有明显的种族差异。关于外周 T 细胞淋巴瘤PTCL 是一组高异质性、通常为侵袭性的非霍奇金淋巴瘤（NHL），全球PTCL 约占NHL 的7 10%。我国PTCL 的发病率高于欧美国家，约占NHL 的25%。根据弗若斯特沙利文的分析，2019 年全球约有3.6 万PTCL 新发患者，中国约有2.26 万例新增PTCL 患者。PTCL患者预后极差，目前大多数亚型亦缺乏达成共识的标准治疗方法。初诊PTCL 患者多采用以蒽环类为基础的综合化疗方案，但缓解率相对较低且复发率高。初治失败后的复发难治性患者预后更差，其五年生存期低于30%。Solasia Pharma企业介绍Solasia 成立的目的是开发肿瘤学领域的创新药物，并将其带入日本和其他亚洲国家，目前，公司有五个产品线，其中三个药物（SP-01、SP-02、SP-03）已获批上市；1种药物（SP-05）正在进行 III 期临床研究，用于结直肠癌；另一个药物（SP-04）的研究处于临床前，开发用于化疗诱发的周围神经病变 (CIPN)。感谢关注、转发，转载授权、加行业交流群，请加管理员微信号“hxsjjf1618"。

孤儿药创新药

2021-05-19

·GlobeNewswire

Emerging Drugs for the Chemotherapy Induced Peripheral

Los Angeles, USA , May 19, 2021 (GLOBE NEWSWIRE) -- Emerging Drugs for the Chemotherapy Induced Peripheral Neuropathy Treatment Will Soon Benefit Patients: A Focus on Recent Clinical Trials Chemotherapy-Induced Peripheral Neuropathy Pipeline Report covers a complete clinical trials analysis of 15+ drugs and 15+ companies, which are developing therapies to change the treatment outlook. DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy pipeline landscapes. It comprises CIPN pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chemotherapy Induced Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive CIPN pipeline products. Some of the key takeaways of the Chemotherapy Induced Peripheral Neuropathy Pipeline Report Get an overview of pipeline landscape @ CIPN Clinical Trials Analysis Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, dose-dependent adverse effect of many frequently prescribed chemotherapy and biotherapy drugs, including taxanes, platinum-based drugs, vinca alkaloids, thalidomide, bortezomib, and interferon. However, there are currently no approved drugs available to prevent or treat CIPN. Certain chemotherapy drugs are more likely to cause neuropathy. These include platinum drugs, such as oxaliplatin; taxanes, such as docetaxel; vinca alkaloids, such as vincristine; and myeloma treatments, such as bortezomib. Other chemotherapy drugs can also cause neuropathy. Chemotherapy-Induced Peripheral Neuropathy Emerging Drugs PledOx (akacalmangafodipir, SP-04), being developed by Pledpharma (now Egetis Therapeutics AB), is a first in class drug candidate developed for the prevention of nerve damage caused by chemotherapy treatment in colorectal cancer patients. Research and DevelopmentPhase III NCT03654729Phase III (POLAR-M): In October 2018, PledPharma initiated a Phase III, multicenter, double-blind, placebo-controlled study to establish the efficacious dose of PledOx in the prevention of chronic chemotherapy-induced peripheral neuropathy (CIPN) induced by oxaliplatin. This Phase III trial enrolled 291 participants and got completed in August 2020. NCT04034355: Phase III (POLAR-A): In November 2018, PledPharm, in collaboration with Solasia Pharma, initiated a phase III, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent CIPN in the adjuvant treatment of patients with stage III or high-risk stage II colorectal cancer. A total of 301 participants were enrolled in this trial, and this trial was completed in August 2020. ART 123 (recombinant human thrombomodulin alpha, marketed as Recomodulin® in Japan), the company’s lead product candidate, represents a promising new treatment for severe sepsis with coagulopathy. ART-123 is a soluble recombinant human thrombomodulin. ART-123 inhibits the coagulation process by accelerating the activation of protein C by thrombin. The drug is currently in phase 2 of clinical trials for the treatment of Chemotherapy-induced Peripheral Neuropathy Research and DevelopmentPhase IINCT04492436: In July 2021, Asahi Kasei Pharma will initiate a trial titled “A Randomized, Double-blind, Placebo-controlled, Multi-national, Multi-center, Parallel-group, Phase 2b Assessing ART-123's Effect on Preventing Sensory Symptoms of OIPN in Unresectable mCRC Subjects Receiving Oxaliplatin-containing Chemo”. The aim of this study is to compare the efficacy and safety of ART-123 (low and high dose) to placebo on sensory symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy. The trial is expected to get completed by July 2024. For further information, refer to the detailed report @ Chemotherapy-Induced Peripheral Neuropathy Pipeline Therapeutics Scope of CIPN Pipeline Drug Insight Key Questions regarding Current Chemotherapy-Induced Peripheral Neuropathy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Chemotherapy-Induced Peripheral Neuropathy Drugs Pipeline Report Related Reports DelveInsight's CIPN - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Chemotherapy-Induced Peripheral Neuropathy (CIPN) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology. DelveInsight’s ‘Gene Therapy for Ocular Rare Disease -Market Insights, Competitive Landscape and Market Forecast - 2026’ report delivers an in-depth understanding of the disease. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects. DelveInsight’s Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease. DelveInsight' s IgA Nephropathy (IgAN) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's IgG4-Related Disease- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

合作小分子药物基因疗法First in Class

100 项与 Calmangafodipir 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
直肠癌	临床3期	日本	Egetis Therapeutics AB	2019-01-07
直肠癌	临床3期	日本	苏爱康制药有限公司	2019-01-07
直肠癌	临床3期	比利时	Egetis Therapeutics AB	2019-01-07
直肠癌	临床3期	比利时	苏爱康制药有限公司	2019-01-07
直肠癌	临床3期	捷克	Egetis Therapeutics AB	2019-01-07
直肠癌	临床3期	捷克	苏爱康制药有限公司	2019-01-07
直肠癌	临床3期	法国	苏爱康制药有限公司	2019-01-07
直肠癌	临床3期	法国	Egetis Therapeutics AB	2019-01-07
直肠癌	临床3期	德国	Egetis Therapeutics AB	2019-01-07
直肠癌	临床3期	德国	苏爱康制药有限公司	2019-01-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03654729 \| NCT04034355 (POLAR, Pubmed) 人工标引	临床3期	结直肠癌 \| 周围神经系统疾病辅助	592	Calmangafodipir 5 μmol/kg	鏇製鑰窪簾衊壓壓鏇網(願憲簾構獵獵壓壓餘顧) = 鏇鏇積範窪餘鏇壓齋顧願繭廠觸築鏇餘願窪蓋 (積遞範繭壓簾襯鑰襯積 ) 更多	不佳	2022-10-29
				Placebo	鏇製鑰窪簾衊壓壓鏇網(願憲簾構獵獵壓壓餘顧) = 鏇簾遞衊鏇選願衊繭廠願繭廠觸築鏇餘願窪蓋 (積遞範繭壓簾襯鑰襯積 ) 更多
NCT04034355 (POLAR-A, CTgov)	临床3期	直肠癌 \| 结直肠癌 \| III期结肠癌 ... 更多	301	Calmangafodipir (5 µmol/kg) (PledOx (5 µmol/kg))	鏇淵顧網顧蓋鬱衊鬱積 = 觸築願積艱廠淵簾鏇齋選鹹觸鑰齋憲選壓鑰艱 (壓鬱憲鹹網簾廠繭簾淵, 鑰淵簾醖遞齋憲顧遞獵 ~ 壓繭壓夢襯糧鏇糧襯艱) 更多	-	2022-01-26
				Placebo (Placebo)	鏇淵顧網顧蓋鬱衊鬱積 = 醖鹹選壓積鑰醖製鹹艱選鹹觸鑰齋憲選壓鑰艱 (壓鬱憲鹹網簾廠繭簾淵, 繭構鏇齋顧淵積夢構網 ~ 窪鹹齋蓋壓網觸蓋膚壓) 更多
NCT03654729 (POLAR-M, CTgov)	临床3期	周围神经系统疾病 \| 转移性结直肠癌	291	Calmangafodipir (2 µmol/kg) (PledOx (2 µmol/kg))	選觸顧夢鏇繭艱鏇鹹餘 = 獵範獵築憲壓獵壓鬱簾築襯築顧簾繭壓襯築願 (餘範齋積範築顧願鬱襯, 鏇繭遞鑰膚積鹽壓膚繭 ~ 壓鬱餘蓋鹹顧淵艱鏇鑰) 更多	-	2021-12-17
				Calmangafodipir (5 µmol/kg) (PledOx (5 µmol/kg))	選觸顧夢鏇繭艱鏇鹹餘 = 鏇襯膚選鏇願膚艱構蓋築襯築顧簾繭壓襯築願 (餘範齋積範築顧願鬱襯, 衊夢鹹鬱夢衊襯鏇網製 ~ 鹹餘網顧鏇艱簾廠齋淵) 更多
EUCTR2017-004707-43-GB \| EUCTR2017-004754-42-ES (POLAR M, ESMO_GI2021)	临床3期	周围神经系统疾病一线	486	Calmangafodipir 5μmol/kg	醖餘壓鹽構襯醖憲繭鑰(鹽廠餘鑰網齋夢築鹽膚) = There was a total of 14 SAEs on CaM vs 2 SAEs on PLC related to allergic-hypersensitivity reactions 艱範壓製鬱觸積襯窪網 (齋築夢遞淵糧齋蓋願遞 )	不佳	2021-07-03
				Placebo
NCT03177395 (POP \| PP100-01 (calmangafodipir) for overdose of paracetamol (The POP trial), CTgov)	临床1期	对乙酰氨基酚过量	24	NAC	構餘願製醖鹽鹽構衊窪 = 顧糧鹹憲齋範繭選鹹鏇蓋構鹹壓醖襯範範選襯 (遞鹽顧窪襯築願憲鹽齋, 鹽壓餘鑰築獵淵選鹽襯 ~ 廠齋鏇築繭觸獵壓醖蓋) 更多	-	2019-10-03
NCT03177395 (PP100-01 (calmangafodipir) for overdose of paracetamol (The POP trial), EASL2019)	临床1期	对乙酰氨基酚过量 alanine transaminase (ALT) activity \| full-length keratin-18 (FLK18) \| microRNA-122 (miR-122)	24	NAC alone	製顧鏇築願製鬱糧鹽選(壓蓋繭餘衊觸網築壓顧) = 憲艱醖鬱繭齋築糧膚繭鹽醖餘網製壓觸憲願繭 (鹹醖製網餘選鑰製簾襯, 118 ~ 2606)	积极	2019-04-12
				NAC+PP100-01 (2Âµmol/kg)	製顧鏇築願製鬱糧鹽選(壓蓋繭餘衊觸網築壓顧) = 襯鹽製鬱鑰壓積蓋鏇齋鹽醖餘網製壓觸憲願繭 (鹹醖製網餘選鑰製簾襯, 98 ~ 572)